

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
1.	TENOFOVEK BE	I	1. Dr. Seth Owusu Agyei 2. Dr.Kwaku Poku Asante	Kintampo Health Research Centre	Danadams Pharmaceuticals Industry Limited, Accra-Ghana	Approved, yet to start	5 th December, 2016	5 months
2.	AZI4YAWS	III	Prof. Adu Sarkodie	1. Ayensuanor District 2. West Akyem Municipality 3. Upper West Akyem 4. Nkwanta North District	World Health Organization, Geneva - Switzerland	Approved, yet to start	10 th October, 2016	12 months
3.	MAL 073	IIIb	Prof. Tsiri Agbenyega Dr. Seth Owusu Adjei	Malaria Research Center, Agogo Kintampo Health Research Centre	GlaxoSmithKline Pharmaceuticals	Approved, yet to start	September 2016	38 months
4.	ALB_IVM	III	Dr. Nicholas Opoku	Onchocerciasis Chemotherapy Research Centre Government Hospital.	Case Western Reserve University School Of Medicine, 10900 Euclid Ave Cleveland	Actively enrolling participants	December 17, 2014	38 months
5.	CPAP	III	1. Dr. Harry Tagbor 2. Dr. Frank Baiden 3. Dr. Damien Punguyire 4. Dr. Kwadwo Nyarko Jectey	1. Mampong Government Hospital, Mampong 2. Kintampo Municipal Hospital, Kintampo	General Electric (GE) Foundation's Systems Improvement at District Hospitals and Regional Training of Emergency Care (sidHARTE) out of Columbia University	Actively enrolling participants	1. January 13, 2014 2. January 27, 2014	36 months
6.	MMS	III	Pro f. E. Tsiri Agbenyaga	Barekuma Collaborative Community Development Project C/O Komfo Anokye Teaching Hospital, Kumasi	Kirk Humanitarian	Further enrollment suspended	July 17, 2013	48 months
7.	RIFAMPIN VS ISONIAZID	III	Dr. Joseph Baah Obeng	Komfo Anokye Teaching Hospital Chest Clinic, Kumasi.	Canadian Institute of Health Research	Enrolment closed on Dec 22, 2014; participants are receiving treatment	August 8, 2011	60 months
8.	MAL 094	IIb	Prof. Tsiri Agbenyega	Malaria Research Center, Agogo	GlaxoSmithKline Biologicals SA	Application Pending Approval	N/A	N/A
9.	MoRiOn	II	Dr. Alexander Yaw Debrah	1. Enchi Government Hospital 2. Communities of	Kumasi Centre for Collaborative Research	Application Pending Approval	N/A	N/A

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
				Aowin/Suaman District W/R	in Tropical Medicine			
10.	ALBIVM K'SI	III	DR. ALEXANDER YAW DEBRAH	Kumasi Centre for Collaborative Research in Tropical Medicine	University Hospitals Case medical Center	Irregular Application	N/A	N/A
11.	ELDON CARD	NYN	Prof. Samuel Ameny Obed	Korle Bu Teaching Hospital, Accra.	Center for Global Child Health, Hospital for sick Children.	Incomplete CTA	N/A	N/A
12.	AX-100 HIV	I	Dr. Kwaku Poku Asante	Kintampo Health Research Centre	Neopharmacie Limited , Germany	Application Pending Approval	N/A	N/A
13.	4P	III	1. Dr. Emmanuel Kwabla Srofenyoh 2. Dr. Patrick Frimpong	Ridge Hospital Accra La General Hospital	Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands	Application Pending Approval	N/A	N/A
14.	BIVEK-E	*	Dr. Kwaku Poku Asante	Kintampo Health Research Center	Danadams Pharmaceutical Industry	Application Pending Approval	N/A	N/A
15.	INVACT	III	Prof. Kwadwo Ansah Koram	Noguchi Memorial Institute For Medical Research	Global Emerging Infections Surveillance and Response System (GEIS) of the US Armed Forces Health Surveillance Center (AFHSC)	Application Pending Approval	N/A	N/A
16.	INSUGEN	IV	N/A	Korle-Bu Teaching Hospital	BIOCON LTD	Application Pending Approval	N/A	N/A
17.	ZIV AFFLIBERCEPT	I	Braimah Imono Zeba	Rentina unit, eye centre, Korle-Bu, Teaching Hospital, Korle-Bu, Accra.	Same as PI	Application Pending Approval	N/A	N/A
18.	MAL 055	III	1. Prof. E. Tsiri Agbenyaga 2. Dr. Seth Owusu Agyei 3. Dr.Kwaku Poku Asante	1. Kintampo Health Research Centre 2. Malaria Research Centre, Agogo.	GlaxoSmithKline Biologicals	Active Phase ended; Final report submitted	August 25, 2009	60 months

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
19.	PRENABELT	*	Dr. Jerry Coleman	Korle-Bu Teaching Hospital, Accra - Korle Bu	Global Innovations for Reproductive Health and Life, USA	Active Phase ended; Final report submitted	September 7, 2015	8 months
20.	AIMS	III	Dr. Shirley Owusu-Ofori	Komfo Anokye Teaching Hospital	Terumo BCT Europe N.V.	Active Phase ended; Final report submitted	March 12, 2014	6 months
21.	MENINGOCOCCAL-A CONJUGATE VACCINE	II	Dr. Patrick Ansah	Navrongo Health Research Centre,	1. SIIL 2. PATH	Active Phase ended; Final report submitted	Oct. 13, 2008	42 months + (12 months ext)
22.	NON-INVASIVE HAEM DEVICE	III	Dr. Sam Newton	Kintampo Health Research Centre, Kintampo	PATH	Active Phase Ended	September 19, 2013	2 months
23.	ROTARIX	III	Prof. George Armah	Navrongo Health Research Centre	PATH	Active Phase Ended	September 5, 2012	7 months
24.	ARTIMIST	III	Dr. Patrick Ansah	Navrongo Health Research Centre	ProtoPharma Limited	Active Phase Ended	June 8, 2012	5 months
25.	GARDASIL	III	Dr. Nana Akosua Ansah	Navrongo Health Research Centre	Merck, Sharp and Dohme Corporation	Active Phase Ended	August 27, 2011	20 months
26.	SMAC	III	Prof. Tsiri Agbenyega	Komfo Anokye Teaching Hospital, Kumasi	University Medical Centre Tubingen	Active Phase Ended	August 17, 2011	16 months
27.	OXYTOCIN	III	Dr. Sam Newton	Kintampo Health Research Centre	PATH	Active Phase Ended	April 26, 2011	12 months
28.	AMARYL M	IV	Dr. Frank Umeh	Korle-Bu Teaching Hospital	Sanofi Aventis	Active Phase Ended	August 15, 2010	7 months
29.	MOXIDECTIN-IVERMECTIN	III	Dr. Nicholas Opoku	Onchocerciasis Chemotherapy Research Centre Government Hospital.	1. Wyeth Research Division of Wyeth Pharmaceuticals Inc. 2. Product Development and Evaluaton unit TDR	Report submitted	July 1, 2010	25 months + (12 months ext.)
30.	EBA	I	Prof. Kwadwo Ansah Koram	Noguchi Momorial Institute of Medical Research	Division of Microbiology and Infectious Diseases (DMID) National Institute of Allergy and Infectious	Active Phase ended	May 1, 2010	18 Months

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
					Diseases (NIAID)			
31.	IPT & SP	III	Dr. Abraham Hodgson	Health Facilities in the Kassena Nankana, Navrongo Health Research Centre	London School of Hygiene and Tropical Medicine	Active Phase Ended	May 2010	32 months
32.	IRON FORTIFICATION	III	Dr. Seth Owusu Agyei	Kintampo Health Research Centre	National Institutes of Health	Active Phase Ended	December 7, 2009	12 Months
33.	ROTASHIELD	III	1. George E. Armah 2. Fred N. Binka 3. Abraham Hodgson	1. War Memorial Hospital, Navrongo 2. Bongo Hospital	International Medica Foundation	Active Phase Ended	August 1, 2009	16 months
34.	AZITHROMYCIN PLUS CHLOROQUINE PHOSPHATE	III	Dr. Patrick Ansah	Navrongo Health Research Centre	Pfizer Laboratories Incorporated, Pfizer Global Research and Development.	Active Phase Ended	April 15, 2008	9 months
35.	CRASH-2	II	Dr. J. C. B. Dakubo	Korle-Bu Teaching Hospital	London School of Hygiene & Tropical Medicine	Active Phase Ended, Lancet publication submitted	January 1, 2008	24 months
36.	PYRONARIDINE ARTESUNATE VRS COARTEM	III	Dr. G. Bedu-Adoo	Komfo Anokye Teaching Hospital	Medicines For Malaria Venture, Switzerland	Active Phase Ended	August, 2007	4 months
37.	MAL 050	III	Dr. Seth Owusu Adjei	Kintampo Health Research Centre	GlaxoSmithKline R&D	Active Phase Ended	April 30,2007	16 months
38.	PFCSP_MVACS_MALARIA	I	Koram Kwadwo A	Tetteh Quarshie Memorial Hospital	Division of Microbiology and Infectious Diseases (DMID) National Institute of Allergy and Infectious Diseases (NIAID)	Active Phase Ended	April 2, 2007	18 Months
39.	ROTATEQ	III	George E. Armah	Navrongo Health Research Centre	1. Merck & Co. 2. PATH	Active Phase Ended	March 26, 2007	18 Months
40.	MEFLOQCHLOAZITH	III	Dr. Abraham Hodgson	Navrongo Health Research Centre	Pfizer Inc	Active Phase Ended	November 2006	12 months

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
41.	MAL 047	II	Seth Owusu Adjei, Kwaku Poku Asante	Kintampo Health Research Centre	GlaxoSmithKline R&D	Active Phase Ended	September 22, 2006	19 Months
42.	CDA	III	Dr. Seth Owusu Agyei Dr. Kwaku Poku Asante	Kintampo Health Research Centre	GlaxoSmithKline R & D	Active Phase Ended	June, 2006	12 months
43.	CDA2	III	Prof. Tsiri Agbenyega	Department of Physiology, School of Medical Sciences, KNUST	GlaxoSmithKline R & D	Active Phase Ended	April, 2006	12 months
44.	NOVASIL	II	Prof. David Ofori Agyei Dr. Nii- Ayi Ankrah	Ejura Sekyedumasi Disrict, Ashanti Region	United States Agency for International Development (USAID) Through The Peanut Collaborative Research Support Program	Active Phase Ended	June 30, 2005	9 Months
45.	TENOFOVIR	II	Dr. Edith Clarke	Ghana Health Service	Family Health International	Active Phase Ended	April 1, 2004	20 months
46.	SAVVY	II	Dr. William Ampofo Dr. Baafuor Kofi Opoku	Noguchi Memorial Institution for Medical Research Komfo Anokye Teaching Hospital	Family Health International	Active Phases Ended	Nov. 01, 2003	32 Months
47.	MAL 063	III	Prof. E. Tsiri Agbenyaga	Malaria Research Centre, Agogo.	Malaria Research Centre, Agogo.	Active Phase Ended	May 1, 2012	52 months
48.	PREGACT	III	1.Dr. Harry Tagbor 2.Dr. Henry Opore Addo	1.Ejisu Government Hospital, Ejisu 2.Juaben Government Hospital, Juaben	Prince Leopold Institute of Tropical Medicine	Active Phase Ended	February 9, 2011	60 months
49.	ESM UBT	*	Dr. Ivy Frances Osei	Field Work	Bill and Melinda Gates Foundation, USA	Study not conducted; Funds from Sponsor withdrawn before initiation	N/A	9 months
50.	FERROQUINE	II	1. Dr. Josephine C.	Noguchi Memorial Institute of	Sanofi-Aventis	Study Closed by	N/A	13 months

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
			Ocran 2. Prof. Kwadwo Ansah Koram	Medical Research	Recherché And Développement	Sponsor. No recruitment was done.		
51.	EBOLA Z	II	Dr. Kwaku Poku Asante Prof. Kwadwo A Koram	1. Kintampo Health Research Centre 2. OCRC, Hohoe	GlaxoSmithKline Biologicals	Application withdrawn	N/A	N/A
52.	EBOLA Z (paediatric)	II	Dr. Kwaku Poku Asante	OCRC, Hohoe	Glaxosmithkline Biologicals, Rue De L'institut, 89 - 1330 Rixensart, Belgium	Application withdrawn	N/A	N/A
53.	ZEBOV	I	Professor Fred Binka	OCRC, Hohoe	Crucell Holland B.V, Represented by Janssen Pharmaceutica (Pty) Ltd	Approved but sponsor withdrew conduct	N/A	N/A
54.	ZEBOV 2	II	Professor Fred Binka	OCRC, Hohoe	Crucell Holland B.V, Represented by Janssen Pharmaceutica (Pty) Ltd	Application withdrawn	N/A	N/A
55.	HYDRANON	I	Prof. David Ofori-Adjei	Noguchi Memorial Institute For Medical Research	General Resonance Technology 1llc	Application Withdrawn	N/A	N/A
56.	SALIF	IIIb	1. Dr. Isaac Osei 2. Dr. Samuel Abora 3. Dr. Fred Adomako - Boateng	Navrongo Health Research Centre Upper East Regional Hospital Kumasi Centre for Collaborative Research	Janssen-Cilag International NV (Sponsor) represented by Clinical Research Africa Ltd.	Application Withdrawn	N/A	N/A
57.	MYCOPIROX_LAGRAY	III	Dr. Luitgard Darko		Lagray Chemical Company, Ltd.	Not Approved	N/A	N/A
58.	TADO	III	1. Prof. Tsiri Agbenyega 2. Dr. Catherine Idara Segbefia	1. Malaria Research Center, Agogo 2. Korle-Bu Teaching Hospital, Accra - Korle Bu	Eli Lilly and Company Indianapolis	Prematurely terminated	1. April 9, 2014 2. April 7, 2014	24 months
59.	WOMAN	III	1. Dr. Anthony K. Dah 2. Dr. Opare Addo Henry Sakyi 3. Dr. Kwadwo Asamoah Nyarko-Jectey	1. Ashanti Mampong Municipal Hospital 2. Komfo Anokye Teaching Hospital	Clinical Trials Unit, London School of Hygiene and Tropical Medicine	Terminated	October 24, 2011	Prematurely ended.

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

TITLE OF STUDY		PHASE	PRINCIPAL INVESTIGATOR	STUDY CENTRE(S)	SPONSORS	STATUS	DATE OF COMMENCEMENT	DURATION OF STUDY
			4. Dr. Chris Opoku Fofie 5. Dr. Chris Bawa					
60.	NEOVITA	III	Dr. Sam Newton	Kintampo Health Research Centre	PATH	Premature Termination	August 15, 2011	36 months
61.	SAR97276A_SANOFI	II	Dr. Seth Owusu-Agyei	Navrongo Health Research Centre	Sanofi Aventis Recherche & Developpement	Study Terminated in October 2009	N/A	N/A
62.	HOHOE ANTIMALARIAL	III	Dr. Margaret Kweku	Hohoe Health Research Centre Onchocerciasis Chemotherapy Research Centre, Hohoe Municipal Hospital, Ghana, Ghana Health Service	Malaria Capacity Development Consortium (MCDC)	FDA DISSOCIATED itself from any data or findings from the study due to violation of its guidelines for conducting clinical trials.	September, 2010	6 months
63.	YAWS	III	Dr. Cynthia Kwakye-Maclean	Ga West District	1. University of Ghana School of Public Health 2. World Health Organization 3. Ghana Health Service, Ga West District	Not Approved. FDA DISSOCIATES itself from any data or findings from the study due to violation of its guidelines for conducting clinical trials.	N/A	N/A
64.	GMZ 2	II / III	Dr. Frank Atuguba	Navrongo Health Research Centre, Navrongo.	Statens Serum Institute	FDA DISSOCIATED itself from any data or findings	May 30, 2011	27 months
65.	CEREBETA	*	Mrs. Rose T. Odotei Adjei	Suntreso Government hospital	Best Environmental Technologies	FDA DISSOCIATED itself from any data Findings	N/A	N/A
66.	AQUAMAT	III	Prof. Tsiri Agbenyega	Komfo Anokye Teaching Hospital	WORLD HEALTH ORGANIZATION	FDA DISSOCIATED itself from any data Findings	N/A	N/A

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

No.	SHORT TITLE	FULL TITLE
1.	4P	A strategy to reduce complications of Hypertensive disorders in Pregnancy and Maternal Mortality by 50% or more. - Polypill for the Prevention of Pregnancy Induced Hypertension and Preeclampsia (4P) Trial
2.	AIMS	African Investigation Of Mirasol System For Whole Blood. Clinical And Biological Efficacy Of Mirasol Treated Fresh Whole Blood For The Prevention Of Transfusion Transmitted Malaria
3.	ALB_IVM	Comparison of Ivermectin alone with Albendazole (ALB) plus Ivermectin (IVM) in their efficacy against Onchocerciasis in the Volta Region, Ghana.
4.	ALBIVM K'SI	Comparism of Ivermectin Alone with Albendazole plus Ivermectin in Their Efficacy against Onchocerciasis
5.	AMARYL M	Clinical Efficacy and Safety of Amaryl M in Patients with Type 2 Diabetes who are inadequately treated by either Glimepride or Metformin Monotherapy or who are already treated With Free Combination Of Glimepride and Metformin in African Countries.
6.	AQUAMAT	An Open Randomized Comparism of Artesunate versus Quinine in the Treatment of Severe Falciparum Malaria in African Children.
7.	ARTIMIST	A Phase III, Randomized, Open Labelled, Active Controlled, Multicentre, Superiority Trial Of Artimist [™] Versus Intravenous Quinine In Children With Severe Or Complicated Falciparum Malaria, Or Uncomplicated Falciparum Malaria With Gastrointestinal Complications
8.	AX-100 HIV	A Double Blind Randomized Control Trial of AX-100 Immun (Liquid) and AX-100 Immun Plus Combination Among Adults Living with HIV In Ghana.
9.	AZI4YAWS	Randomized Controlled Trial Comparing Efficacy of a Single Dose of Treatment of Yaws with 20mg/kg versus 30mg/kg of Azithromycin
10	AZITHROMYCIN PLUS CHLOROQUINE PHOSPHATE	Azithromycin Plus Chloroquine Phosphate versus Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium <i>falciparum</i> Malaria in Children in Africa.
11.	BIVEK-E	An open label prospective evaluation of the efficacy, effectiveness and tolerability of fixed dose BIVEK-E (lamivudine/zidovudine/efavirenz) antiretroviral combination therapy for the treatment of HIV in Ghana.
12	CDA	A multicenter, randomized, double blind study to compare the efficacy and safety of CDA versus Artemether-Lumefantrine in the treatment of acute uncomplicated <i>P. falciparum</i> malaria in children and adults in Africa.
13	CDA2	A multicenter, randomized, double blind study to compare the efficacy and safety of CDA versus chlorproguanil-dapsone in the treatment of acute uncomplicated <i>P. falciparum</i> malaria in children and adults in Africa.
14	CEREBETA	Efficacy of Beta-Glucans from Barley and Maintenance of Normal Blood LDL-Cholesterol Concentrations: A Randomized Control Study in Ghana.

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

15	CPAP	Clinical Trial Evaluating the Difference in Mortality Rates in Children in Ghana Receiving Continuous Positive Airway Pressure (CPAP) Versus Those Who Do Not.
16	CRASH-2	A Large Randomized Placebo Controlled Trial, among trauma patients with or at risk of significant Haemorrhage, of the Effects of Anti-Fibrinolytic treatment on Death And Transfusion requirement
17	EBA	Double-Blinded, Placebo-Controlled Dosage-Escalation Study and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi Immune Adults
18	EBOLA Z	A Phase 2, randomized, observer-blind, placebo-controlled, multi-country study to assess the safety and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational recombinant chimpanzee adenovirus Type 3 - vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), in adults 18 years of age and older in Africa
19	ELDON CARD	Using Eldon Card for Testing of Maternal and Newborn Blood Group in Comparison with the Standard Laboratory Method of Blood Group Testing in Accra, Ghana
20	ESM UBT	A Multi-Centre Prospective Trial on the Impact of the Introduction of Condom-Based Uterine Balloon Tamponade for Uncontrolled Postpartum Hemorrhage
21	FERROQUINE	Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated with Artesunate versus a Positive Calibrator (Amodiaquine Associated with Artesunate) In African Adult Patients with Uncomplicated Malaria
22	GARDASIL	Evaluation Of Safety And Immunogenicity Of Gardasil tm In Healthy Females Between 9 And 26 Years Of Age In Subsaharan Africa
23	GMZ 2	Randomized, Controlled, Double-Blind, Multicentre Study To Evaluate The Efficacy, Safety And Immunogenicity Of GMZ2 Candidate Malaria Vaccine In Gabonese, Burkinabe, Ghanaian And Ugandan Children Aged 12-60 Months
24	HOHOE ANTIMALARIAL	A Phase III of the Assessment of the Efficacy, Tolerability and Ease of Administration of, Dihydroartemisinin Plus Piperaquine and and Artesunate Plus Sulfamethoxypyrazine Plus Pyrimethamine for preventing Malaria in Ghanaian Children
25	HYDRANON	Hydranon® solution (GR-08) in healthy adult volunteers
26	INVACT	In vivo Efficacy of Artemisinin Combination Therapy to Explore Laboratory and Parasitological Markers of Artemisinin Resistance in Uncomplicated Plasmodium falciparum Malaria in Ghana.
27	IPT & SP	Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine (SP) Versus Intermittent Screening And Treatment Of Malaria In Pregnancy
28	INSUGEN	POST MARKET SURVEILLANCE STUDY OF INSUGEN 30/70

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

29	IRON FORTIFICATION	Seasonal Impact Of Iron Fortification On Malaria Incidence In Ghanaian Children
30	MAL 047	Randomized, Controlled, Partially-Blind Study Of The Safety And Immunogenicity Of Glaxosmithkline Biologicals' Candidate <i>Plasmodium Falciparum</i> Vaccines RTS,S/AS02D And RTS,S/AS01E, When Administered IM According To A Three Dose Schedules In Children Aged 5 To 17 Months Living In Ghana.
31	MAL 050	Randomized, Open, Controlled Study Of The Safety Of The And Immunogenicity Of GSK Biologicals' Candidate Plasmodium Falciparum Malaria vaccine RTS, S/AS01E when incorporated into an expanded program on immunization (EPI) regimen that includes DTPWHEPB/HIB.OPV, Measles and yellow fever vaccination in infants living in malaria- Endemic Regions- 050
32	MAL 055	Double Blind (Observer Blind), Randomised, Controlled Multicentre Study To Evaluate In Infants And Children, The Efficacy Of RTS,S/AS10E Candidate Vaccine Against Malaria Disease Caused By P. Falciparum Infection Across Diverse Malaria Transmission Settings In Africa
33	MAL 063	Randomized, Open, Controlled Study To Evaluate The Immune Response To The Hepatitis B Antigen Of The RTS,S /AS01E Candidate Vaccine, When Administrated As Primary Vaccination Integrated Into An EPI Regimen To Infants Living In Sub-Saharan Africa
34	MAL 073	Phase IIIb randomized, open, controlled, multi-center study to evaluate the immunogenicity and safety of the RTS,S/AS01E candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9 months of age with or without co-administration of measles, rubella and yellow fever vaccines followed by an RTS,S/AS01E booster vaccination 18 months post Dose 3, to children living in sub-Saharan Africa
35	MAL 094	Phase IIb randomized, open-label, controlled, multi-centre study of the efficacy, safety and immunogenicity of GSK Biologicals' candidate malaria vaccine RTS,S/AS01E evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age living in Sub-Saharan Africa.
36	MEFLOQCHLOAZITH	A Phase III, Randomized, Opened-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa.
37	MENINGOCOCCAL-A CONJUGATE VACCINE	A Phase II, Double Blind, Randomized, Controlled, Dose Ranging Study to Evaluate the Safety, Immunogenicity Dose Response and Schedule Response of a Meningococcal A Conjugate Vaccine administered concomitantly with local EPI vaccines in Healthy Infants.
38	MMS	The Use Of A Multiple Micronutrient Supplement In Women Of Reproductive Age
39	MoRiOn	The Efficacy of Rifapentine 900mg/d plus Moxifloxacin 400mg/d given for 14 or 7 days against Onchocerciasis - a Randomized, Controlled, Parallel-Group, Open Label, Phase II Pilot Trial
40	MOXIDECTIN-IVERMECTIN	Randomized, single-ascending dose, Ivermectin-controlled, double-blind, safety, tolerability, pharmacokinetic and efficacy study of orally administered Moxidectin in participants with <i>Onchocerca volvulus</i> Infection
41	MYCOPIROX_LAGRAY	Randomized, open labelled trial to evaluate the efficacy, safety and tolerability of mycopirox vaginal cream in the treatment of mixed infection vaginitis
42	NEOVITA	Efficacy Of Neonatal Vitamin A Supplementation In Improving Child Survival In Rural Ghana

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

43	NON-INVASIVE HAEM DEVICE	A Comparison Of Hemoglobin Values As Measured By The Pronto And Pronto 7 Non-Invasive Hemoglobin Devices, The Hemocue Hb 201+, And A Hematology Analyzer Among Pregnant Women Attending Antenatal Care Clinic In Ghana
44	NOVASIL	Safety and Efficacy Evaluation of Novasil: Strategy for the Protection of Humans from Aflatoxin Toxicity
45	OXYTOCIN	Determining The Effect Of Prophylactic Administration Of Oxytocin In Uniject™ By A Community Health Officer On Post Partum Haemorrhage At Home Births In The Kintampo North And South Districts Of Ghana
46	PFCSP_MVACS_MALARIA	Partial Double-Blind, Randomized Study Of PFCSP DNA/MVA Prime Boost Vaccine
47	PREGACT	Evaluating The Safety And Efficacy Of Artemisinin-Based Combination Treatments For African Pregnant Women With Malaria
48	PRENABELT	A Maternal Device to Reduce the Risk of Stillbirth and Low-Birth Weight
49	PYRONARIDINE ARTESUNATE VRS COARTEM	Randomized multicentre clinical study to assess the safety and efficacy of fixed dose formulation of oral pyronaridine artesunate tablet versus coartem in children and adult patients with acute uncomplicated plasmodium falciparum malaria
50	RIFAMPIN VS ISONIAZID	A Randomized Clinical Trial of 4 months Rifampin versus 9 months Isoniazid for treating Latent TB Infection
51	ROTARIX	Immunogenicity Of The Human Rotavirus Vaccine (Rotarix™) At Varying Schedules and Ages In Rural Ghana
52	ROTASHIELD	The Randomized, Double-Blind, Placebo-Controlled Evaluation Of The Efficacy, Immunogenicity, and Safety of 2 Single Doses of RRV-TV in Neonates/Infants
53	ROTATEQ	Efficacy, Safety and Immunogenicity Of Rotateq™ Among Infants In Africa and Asia.
54	SALIF	A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRT/-based Suppressed Patients Switching At Low HIV-1 RNA Into Fixed Dose Combinations
55	SAR97276A_SANOFI	A Multicentre, Open Label, Efficacy And Safety Of Parenteral Sar97276a In The Treatment Of Symptomatic Uncomplicated And Severe Malaria In Adults And Children
56	SAVVY	Randomised Controlled Trials of Savvy In HIV
57	SMAC	A Comparative, Open Label, Dose And Regimen Optimization Follow-Up Study Of Intravenous And Intramuscular Artesunate In African Children With Severe Malaria.
58	TADO	Double-Blind, Randomized, Efficacy And Safety Comparison Of Prasugrel And Placebo In Pediatric Patients With Sickle Cell Disease
59	TENOFOVEK BE	A balanced, randomized, two treatment, two-period, two-sequence single dose crossover, open-label, analyst blind and single centre bioequivalence study test product; Tenofovek of Danadams Pharmaceuticals Industry Ltd., Ghana and reference product; Viread (Gilead Sciences, Inc., CA, USA) in healthy, Ghanaian adult, male, human participants under fasting conditions.

CLINICAL TRIAL REGISTRY - FOOD AND DRUGS AUTHORITY, GHANA

60	TENOFOVIR	A Phase II Study for Tenofovir Disoproxyl Fumarate for Prevention of HIV
61	WOMAN	Tranexamic Acid For The Treatment Of Postpartum Haemorrhage: An International, Randomized, Double Blind, Placebo Controlled Trial
62	YAWS	Single Dose Oral Azithromycin Versus Injection Benzathine Penicillin For The Treatment Of Yaws - A Randomized Clinical Trial In Some Endemic Communities In Ghana
63	ZEBOV	A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-FILO and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults
64	ZIV AFFLIBERCEPT	phase I, Safety of ZIV-AFLIBERCEPT in retinal diseases in Ghanaian population
65	*	Feasibility Studies
66	N/A	Study not started/ Application withdrawn /Not approved / Terminated / FDA dissociation from Trial data
67	NYN	Not yet known
68	Active Trials	
69	Applications pending approval	
70	Active phase ended	
71	Trials closed by Sponsor before commencement	
72	Application withdrawn by Sponsor before FDA approval	
73	Trials Not Approved	
74	Trials terminated by FDA/Sponsor	
75	Dissociation of Trial Data by FDA	

Last Date Updated: 1st May, 2017.